Aerg.Pk
AERG.PK operates in the healthcare equipment industry, specializing in advanced medical equipment and technology, and generates revenue primarily through the development, production, and sale of medical devices and related technologies.
Business. AERG.PK operates in the healthcare equipment industry, specializing in advanced medical equipment and technology, and generates revenue primarily through the development, production, and sale of medical devices and related technologies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AERG.PK operates in the healthcare equipment industry, specializing in advanced medical equipment and technology, and generates revenue primarily through the development, production, and sale of medical devices and related technologies.
The company's capital structure is characterized by a very low debt-to-equity ratio of 0.01, indicating a strong reliance on equity financing and minimal leverage. With $6.44 million in cash and equivalents and $1.5 million in total liabilities, the company maintains a current ratio of 8.29, suggesting robust short-term liquidity. However, the company's operating cash flow is negative at -$9.24 million, and free cash flow is -$15.60 million, indicating significant cash outflows from operations.
Profitability metrics are severely negative, with a return on equity of -1.97 and a return on assets of -1.64, both well below the typical thresholds for a healthy business in the healthcare equipment industry. The company reported a net loss of $14.87 million and an operating loss of $14.93 million, which is a clear sign of operational inefficiencies or market challenges.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the data does not specify the regions where the company operates or generates revenue.
The company's growth trajectory is currently negative, with a net loss and declining cash flows. No specific revenue growth or decline percentages are provided for the current or next fiscal year, but the financial snapshot suggests a challenging operating environment. The company's capital expenditures of -$1.23 million indicate a reduction in investment in long-term assets, which may signal a strategic shift or financial constraints.
Risk factors include a low liquidity score and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's negative operating and free cash flows suggest potential liquidity risks in the future if the trend continues. There are no indications of dilution pressure from recent equity issuances or shelf registrations.
Recent events or filings have not been disclosed in the available data, and there are no transcripts or other public communications that provide insight into the company's recent strategic or operational developments.
- The company is highly liquid with a current ratio of 8.29 but is experiencing significant negative cash flows from operations.
- Profitability is severely negative, with a return on equity of -1.97 and a return on assets of -1.64.
- The company has a minimal debt load, with a debt-to-equity ratio of 0.01, but is not generating positive returns on its capital.
- There is no immediate liquidity or dilution risk, but the negative cash flows and operating losses may pose future challenges.
- The company's business is not diversified by segment or geography, increasing its exposure to sector-specific risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- AERG.PK Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Bradford Thomas AdamczykExecutive Chairman of the Board
- Christopher Wayne DonagheyPresident, Chief Executive Officer, Director
- Gregory J. QuarlesPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Net margin (FY 2025-12-31): -3,221.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -62.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -81.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -62.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -75.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -75.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 3,805.1%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 1,149.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.20xDerived (calculated)
- Current ratio (FY 2025-12-31): 8.29xDerived (calculated)
- Return on assets (FY 2025-12-31): -164.1%Derived (calculated)
- Return on equity (FY 2025-12-31): -196.7%Derived (calculated)
- Gross margin (FY 2025-12-31): 54.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 598.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 337.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,824.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -10.3%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -85.6%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -73.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -81.0%Derived (calculated)
- Net income (annual): USD -14.87MSEC XBRL filing
- Cash & equivalents (annual): USD 6.44MSEC XBRL filing
- Total operating expenses (annual): USD 15.18MSEC XBRL filing
- Gross profit (annual): USD 249.11KSEC XBRL filing